HomepageARCT • NASDAQ
add
Arcturus Therapeutics Holdings Inc
$Â 6,68
Na sluitingstijd:(0,15%)+0,010
$Â 6,69
Gesloten: 13 mrt, 19:01:11 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$Â 7,00
Dag-range
$Â 6,64 - $Â 7,25
Jaar-range
$Â 5,86 - $Â 24,14
Beurswaarde
189,87Â mln. USD
Gem. volume
468,98K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 7,20Â mln. | -68,39% |
Bedrijfskosten | 14,03Â mln. | 13,30% |
Netto inkomsten | -29,08Â mln. | 3,09% |
Netto winstmarge | -404,10 | -206,60% |
Winst per aandeel | -1,03 | 7,21% |
EBITDA | -30,62Â mln. | 5,99% |
Effectief belastingtarief | 0,01% | — |
Balans
Totale activa
Totale passiva
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 230,91Â mln. | -2,58% |
Totale activa | 271,15Â mln. | -21,19% |
Totale passiva | 57,16Â mln. | -44,55% |
Totaal aandelenvermogen | 213,98 mln. | — |
Uitstaande aandelen | 28,42 mln. | — |
Koers-boekwaardeverhouding | 0,93 | — |
Rendement op activa | -28,28% | — |
Rendement op kapitaal | -31,98% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -29,08Â mln. | 3,09% |
Operationele kasstroom | -16,23Â mln. | -5.613,73% |
Kasstroom uit beleggingen | 88,00K | — |
Kasstroom uit financiering | 11,69Â mln. | 8.622,39% |
Nettomutatie in liquide middelen | -4,45Â mln. | -2.867,33% |
Vrije kasstroom | 50,91Â mln. | 434,06% |
Over
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
Opgericht
2013
Website
Werknemers
109
